贝伐珠单抗联合紫杉醇治疗复发性卵巢癌疗效分析  

Efficacy of Bevacizumab Combined with Paclitaxel in the Treatment of Relapsed Ovarian Cancer

作　　者：崔艳艳[1] 

机构地区：[1]赤峰学院附属医院肿瘤内科,内蒙古赤峰024000

出　　处：《肿瘤基础与临床》2017年第4期286-288,共3页journal of basic and clinical oncology

摘　　要：目的观察贝伐珠单抗联合紫杉醇治疗复发性卵巢癌的疗效和不良反应。方法 35例复发性卵巢癌患者应用贝伐珠单抗联合紫杉醇作为二线或多线治疗。结果 35例患者均可进行疗效评价,有效率为54.29%,疾病控制率为82.86%。不良反应主要有骨髓抑制、恶心呕吐、高血压、蛋白尿等,大多为轻度。结论贝伐珠单抗联合紫杉醇治疗复发性卵巢癌安全有效,患者可耐受,是复发性卵巢癌可选择的治疗方案之一。Objective To observe the efficacy and toxicities of bevacizumab combined with paclitaxel in the treatment of relapsed ovarian cancer. Methods Thirty-five patients with relapsed ovarian cancer were enrolled, and received bevacizumab combined with paclitaxel. Results Thirty-five patients were evaluated for efficacy, the re- sponse rate was 54.29%, the disease control rate was 82.86%. The major toxicities were mild myelosuppression, nausea and vomiting, hypertension, proteinuria. Conclusion Bevacizumab combined with paclitaxel is safe and effect in the treatment of patients with relapsed ovarian cancer.

关 键 词：贝伐珠单抗 紫杉醇 复发性卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤] R730.58[医药卫生—临床医学]